Suppr超能文献

贝林司他口服混悬剂的吸收机制研究。

Mechanistic Study of Belinostat Oral Absorption From Spray-Dried Dispersions.

机构信息

Drug Product Development and Innovation, Lonza Pharma and Biotech, Bend, Oregon 97703.

Dosage Form and Delivery Services, Lonza Pharma and Biotech, Bend, Oregon 97703.

出版信息

J Pharm Sci. 2019 Jan;108(1):326-336. doi: 10.1016/j.xphs.2018.09.031. Epub 2018 Oct 6.

Abstract

Spray-dried dispersions (SDDs) are an important technology for enhancing the oral bioavailability of poorly water-soluble drugs. To design an effective oral SDD formulation, the key rate-determining step(s) for oral drug absorption must be understood. This work combined in vivo and in vitro tests with in silico modeling to identify the rate-determining steps for oral absorption of belinostat SDDs made with 3 different polymers (PVP K30, PVP VA64, and HPMCAS-M). The goal was developing a belinostat SDD formulation that maximizes oral bioavailability (ideally matching the performance of a belinostat oral solution) and defining critical performance attributes for formulation optimization. The in vivo pharmacokinetic study with beagle dogs demonstrated that 1 of the 3 SDDs (PVP K30 SDD) matched the performance of the oral solution. In vitro data coupled with in silico modeling elucidated differences among the SDDs and supported the hypothesis that absorption of belinostat in the small intestine from the other 2 SDDs (PVP VA64 and HPMCAS-M) may be limited by dissolution rate or reduced drug activity (maximum concentration) in the presence of polymer. It was concluded that drug concentration in the stomach before emptying into the proximal intestine is a key factor for maximizing in vivo performance.

摘要

喷雾干燥分散体(SDD)是提高难溶性药物口服生物利用度的重要技术。为了设计有效的口服 SDD 制剂,必须了解口服药物吸收的关键限速步骤。这项工作将体内和体外测试与计算机模拟相结合,以确定使用 3 种不同聚合物(PVP K30、PVP VA64 和 HPMCAS-M)制成的贝林司他 SDD 的口服吸收的限速步骤。目标是开发一种贝林司他 SDD 制剂,最大限度地提高口服生物利用度(理想情况下与贝林司他口服溶液的性能相匹配),并确定制剂优化的关键性能属性。用比格犬进行的体内药代动力学研究表明,3 种 SDD 中的 1 种(PVP K30 SDD)与口服溶液的性能相匹配。体外数据结合计算机模拟阐明了 SDD 之间的差异,并支持了这样的假设,即来自其他 2 种 SDD(PVP VA64 和 HPMCAS-M)的贝林司他在小肠中的吸收可能受到溶解速率或聚合物存在时药物活性(最大浓度)的限制。结论是,在排空到近端肠之前胃中的药物浓度是最大限度提高体内性能的关键因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验